_256_384.png){kind=logo}
Digitisation | February 09, 2024
Qure.ai adds new FDA breakthrough device status for qSpot-TB
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
An accomplished R&D leader and champion of the application of AI to drug discovery
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
He is also inducted as a member of the management council and senior management personnel of the company
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
NEIAFMR to be developed as the national hub for folk medicine
US FDA approval based on NEURO-TTRansform Phase III results
Subscribe To Our Newsletter & Stay Updated
